BONFIRE - Beta-blockers discontinuation in patients presenting heart failure with recovered left ventricular ejection fraction - APHP230833

Assistance Publique Hopitaux De Paris0 个研究点目标入组 1,300 人开始时间: 2024年3月4日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Assistance Publique Hopitaux De Paris
入组人数: 1,300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Age = 18 years-old, Ability to provide written informed consent to participate to the study, Patient affiliated to Social Security, Established diagnosis of HF for more than 12 months, from an ischemic or a non-ischemic origin, With a documented history of reduced left ventricular ejection fraction (LVEF = 45%), followed by a normalisation of LVEF (= 50 % for the last 6 months) assessed by cardiac echography., With a left ventricular end diastolic volume indexed to body surface area (LVEDVi) within the normal range (=74ml/m2 in men and =61 ml/m2 in women), No or mild symptoms of HF (defined as NYHA functional class I or II), No heart failure-related hospital admission within the last six months, Currently receiving a beta-blocker indicated for chronic heart failure (i.e., bisoprolol or carvedilol or metoprolol or nebivolol) whatever the dose used, for at least 12 months, And receiving the guideline-directed optimal medical therapy for at least 12 months (i.e., maximal tolerated dose of SGLT2i, of RAAS blocker (Angiotensin receptor neprilysin inhibitor OR Angiotensin-converting-enzyme-inhibitors OR Angiotensin II receptors blockers), and of MRA if tolerated). Loop diuretics use is adjusted to congestive signs according to physicians’ decision, With or without ICD

排除标准

•Atrial, supra-ventricular, or ventricular arrhythmias, in the last 12 months and/or requiring beta-blockers according to investigator, Hepatic insufficiency classified as Child-Pugh B or C at the inclusion Visit, Any past solid organ transplantation or planned organ transplantation within 12 months, Any condition other than HF that could limit survival to less than one year, Pregnancy or breastfeeding women or women of childbearing potential without adequate contraceptive method, Current participation in another interventional trial, Patient under legal protection (protection of the court, or in curatorship or guardianship)., Any disorder, unwillingness or inability, which in investigator’s opinion, might jeopardize the patient’s safety or compliance with the protocol, Uncontrolled arterial hypertension according to investigator decision, Symptomatic angina or evidence of infra-clinic myocardial ischemia requiring beta-blockers according to investigator decision, Cardiac resynchronization therapy, Extra-cardiac conditions requiring beta-blockers (migraine, essential tremor, prevention of bleeding from esophageal varices in patients with liver cirrhosis, adrenergic symptoms of hyperthyroidism…) according to investigator decision, History of severe outcomes at beta-blockers interruption: HF relapse, occurrence of arrythmias, Severe valvulopathy, restrictive, infiltrative or hypertrophic cardiomyopathy, constrictive pericarditis, or acute myocarditis within 3 months prior to inclusion visit, Planned coronary, carotid, or peripheral artery revascularization known at the day of inclusion, Chronic renal failure with eGFR <20mL/Min per 1.73m² (CKD-Epi) at inclusion

研究者

发起方

Assistance Publique Hopitaux De Paris

相似试验

进行中（未招募）

1 期

BBLOQ-2017MedDRA version: 20.0Level: HLGTClassification code 10019280Term: Heart failuresSystem Organ Class: 10007541 - Cardiac disordersHeart Failure

EUCTR2017-005077-39-ESInstituto de Investigación Sanitaria INCLIVA52

进行中（未招募）

1 期

Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized studyHeart failure

EUCTR2021-001327-41-ESFundación para la formación e investigación sanitarias de la Región de Murcia60

招募中

1 期

Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE)MedDRA version: 20.0Level: LLTClassification code: 10019279Term: Heart failure Class: 10007541Heart Failure

CTIS2023-504946-70-00Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia60

招募中

2 期

Beta-Blocker Withdrawal in Heart Failure with Preserved Ejection Fraction and Chronotropic Incompetence (BRILLIANT)

JPRN-jRCT1031210030Obokata Masaru150

招募中

不适用

ong-term beta-blocker therapy after acute myocardial infarctioDiseases of the circulatory system

KCT0005903Samsung Medical Center2,500